The Food and Drug Administration (FDA) is offering a funding opportunity titled "Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional." This initiative aims to enhance the understanding of how food and acid-reducing agents affect the absorption of amorphous solid dispersion (ASD) drug products by developing and validating an in vitro mechanistic methodology. The research will focus on evaluating the impact of various food types and elevated gastric pH on drug interactions, ultimately informing regulatory decision-making to mitigate risks associated with high-risk generic oral drug products. The total funding available is $500,000, with two awards anticipated, and applications are due by March 31, 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information.